The Use of a Quality of Life Questionnaire in Patients With Lung Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01213745
Recruitment Status : Unknown
Verified October 2010 by Royal Marsden NHS Foundation Trust. Recruitment status was: Recruiting
This study will investigate the effectiveness of using the European Organisation for Research and Treatment of cancer Core Quality of Life Questionnaire (EORTC QLQ-C30 + LC 13) to identify and target therapies in patients with lung cancer. The study will assess whether using the questionnaire will result in an improvement in QoL.
Condition or disease
Other: InterventionOther: AttentionOther: Control
Patients with lung cancer who have completed a course of treatment (or who are in-between treatment) at the Royal Marsden Hospital would be eligible for inclusion in the study. Participants will be randomised into 3 groups. Group 1 - this group will complete the QoL questionnaire and will receive targeted therapies by a doctor (and other members of the oncology team) during a clinic consultation. Group 2 - will complete the QoL questionnaire however the questionnaire will not be seen by the doctor during a clinic consultation. Group 3 - the control group will not complete the QoL questionnaire before a clinic consultation. All patients will complete a diary of all contact they have with health care professionals during the study. The study will last for 6 weeks and at the end of the study all patients will complete the QoL questionnaire.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
male or female age > 18 years
patients who are able to adequately understand written and spoken english
diagnosis of lung cancer (non small cell, small cell, mesothelioma)
no plan to commence treatment (chemotheraphy, targeted therapies, radioterhapy, surgery) with 6 weeks
both radically or palliatively treated patients remain eligible
patients whose toxicities from their primary treatment has resolved or have stabilised for a period of 7 days
patients are taking part on any other QoL studies
taking part in any other studies that requires QoL questionnaires, extra visits or investigations
currently on treatment (chemotherapy, radiotherapy, surgery or targeted therapies)
they have on going toxicities from their treatment which have not been stablised (required intervention within last 7 days)